{
    "ticker": "RLAY",
    "name": "Relay Therapeutics, Inc.",
    "description": "Relay Therapeutics, Inc. is a biopharmaceutical company revolutionizing drug discovery through its groundbreaking use of protein motion analysis and machine learning technology. Founded in 2016, Relay focuses on precision medicine, particularly in the field of oncology, by leveraging its proprietary platform to develop therapies tailored to the unique characteristics of individual tumors. The company is dedicated to understanding the dynamic nature of proteins and their interactions, which allows for the identification of novel drug candidates against difficult-to-target proteins. Relay's innovative approach has the potential to significantly enhance the efficacy of treatments for cancer patients. The company's lead candidate, RLY-2608, is currently in clinical trials, targeting specific mutations in cancer cells, showcasing Relay's commitment to advancing personalized medicine. Relay Therapeutics aims to transform the landscape of cancer treatment and improve patient outcomes through its cutting-edge research and development efforts.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2016",
    "website": "https://www.relaytherapeutics.com",
    "ceo": "Sanford J. Markowitz",
    "social_media": {
        "twitter": "https://twitter.com/RelayTherapeutics",
        "linkedin": "https://www.linkedin.com/company/relaytherapeutics/"
    },
    "investor_relations": "https://investors.relaytherapeutics.com",
    "key_executives": [
        {
            "name": "Sanford J. Markowitz",
            "position": "CEO"
        },
        {
            "name": "David L. C. Moller",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapeutics",
            "products": [
                "RLY-2608"
            ]
        }
    ],
    "seo": {
        "meta_title": "Relay Therapeutics, Inc. | Precision Medicine and Drug Discovery",
        "meta_description": "Discover Relay Therapeutics, Inc., a leader in precision medicine utilizing advanced protein motion analysis and machine learning for drug discovery.",
        "keywords": [
            "Relay Therapeutics",
            "Biotechnology",
            "Cancer Treatment",
            "Precision Medicine",
            "Drug Discovery"
        ]
    },
    "faq": [
        {
            "question": "What does Relay Therapeutics do?",
            "answer": "Relay Therapeutics focuses on drug discovery using protein motion analysis and machine learning to develop precision medicines, particularly in oncology."
        },
        {
            "question": "Who is the CEO of Relay Therapeutics?",
            "answer": "Sanford J. Markowitz is the CEO of Relay Therapeutics, Inc."
        },
        {
            "question": "Where is Relay Therapeutics headquartered?",
            "answer": "Relay Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is Relay's lead product?",
            "answer": "Relay's lead product candidate is RLY-2608, targeting specific mutations in cancer cells."
        },
        {
            "question": "When was Relay Therapeutics founded?",
            "answer": "Relay Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "NVTA",
        "CLVS",
        "EDIT",
        "CRSP"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "MRNA"
    ]
}